What is SKYE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SKYE?

P/E (TTM) is n/a and 52-week range is $1.50 to $14.51 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SKYE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SKYE?

The company profile lists revenue (TTM) near $280K, net income (TTM) near $-1,000K, EPS (TTM) near $-7.93 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Skye Bioscience Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 35.1M shares outstanding, ISIN US83086J2006 when available from company profile and filing metadata.

Skye Bioscience Inc

$SKYE

Health Care · Biotechnology

IR Run Scenarios

$1.69

+0.60%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. The company is headquartered in San Diego, California and currently employs 12 full-time employees. The company went IPO on 2014-02-24. The firm is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The firm is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The firm's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

Employees

Website

skyebioscience.com/

IPO

2014-02-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)